FIELD: medicine.
SUBSTANCE: invention relates to pharmacology and medicine, in particular to application of combination of DPP IV inhibitor or its pharmaceutically acceptable sal with at least one inhibitor of angiotensin converting enzyme (ACE), selected from the group, including benazepril, enapril, lisinopril and ramipril; or in each case with its pharmaceutically acceptable salt; for preparation of medication for prevention, arrested development and treatment of hypertension. Invention provides amelioration of hypertensive patients, and also allows to enlarge the range of medications for hypertension treatment.
EFFECT: amelioration of hypertensive patients and enlargement of range of medications for hypertension treatment.
2 cl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF DIPEPTIDYLPEPTIDASE IV INHIBITORS | 2004 |
|
RU2385723C2 |
| USE OF RKS INHIBITORS IN DIABETES RELATED COMPLICATIONS | 2007 |
|
RU2447892C2 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING SELECTIVE AGONIST OF IMIDAZOLINE RECEPTOR I1 AND BLOCKER OF ANGIOTENSIN II RECEPTOR | 2004 |
|
RU2362561C2 |
| AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR TREATING OR PREVENTING DIABETES | 2010 |
|
RU2550508C2 |
| COMPOSITION FOR PREVENTING OR TREATING RENAL DISEASES, CONTAINING DPP-IV INHIBITOR | 2014 |
|
RU2652343C2 |
| SYNERGETIC COMBINATIONS CONTAINING RENIN INHIBITOR AND INTENDED FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2006 |
|
RU2346703C2 |
| DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
| RENIN INHIBITOR-CONTAINING SYNERGETIC COMPOSITIONS DESIGNATED FOR TREATMENT OF CARDIOVASCULAR DISEASE | 2001 |
|
RU2310443C2 |
| SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
